Asia Pacific Migraine Treatment Market
Tamaño del mercado en miles de millones de dólares
Tasa de crecimiento anual compuesta (CAGR) :
% 
 Período de pronóstico |
2022 –2029 |
 Tamaño del mercado (año base) |
USD 2.38 Billion |
 Tamaño del mercado (año de pronóstico) |
USD 4.67 Billion |
 Tasa de crecimiento anual compuesta (CAGR) |
% |
| Jugadoras de los principales mercados |
>Mercado de tratamiento de la migraña en Asia-Pacífico, por tipos (episódica, migraña con aura, crónica y otras), tratamiento (tratamiento agudo/abortivo, tratamiento preventivo/profiláctico, terapias y dispositivos no farmacológicos), vía de administración (oral, parenteral, aerosoles nasales y otros), tipo de producto (con receta y sin receta), tipo (de marca y genérico), usuario final (hospitales, clínicas, atención domiciliaria, otros), canal de distribución (farmacias hospitalarias, farmacias minoristas, farmacias en línea y otras): tendencias de la industria y pronóstico hasta 2029
Análisis y tamaño del mercado
La migraña es un trastorno cerebral común e incapacitante. El dolor de cabeza es responsable del 4,4 por ciento de todas las visitas a la medicina general, casi el 5 por ciento de todos los ingresos hospitalarios por razones médicas y más del 20 por ciento de las consultas ambulatorias de neurología. La migraña afecta aproximadamente al 20 por ciento de las personas en algún momento de sus vidas; los estudios epidemiológicos muestran que el 4,5 por ciento de la población de Europa occidental sufre dolores de cabeza al menos 15 días al mes, mientras que los estudios globales sugieren que aproximadamente el 1 por ciento de la población mundial sufre migraña crónica.
Data Bridge Market Research analiza que el mercado de tratamiento de la migraña, que fue de USD 2.38 mil millones en 2021, se disparará hasta USD 4.67 mil millones para 2029, y se espera que experimente una CAGR del 8,80% durante el período de pronóstico de 2022 a 2029. Además de los conocimientos del mercado, como el valor de mercado, la tasa de crecimiento, los segmentos del mercado, la cobertura geográfica, los actores del mercado y el escenario del mercado, el informe de mercado curado por el equipo de Data Bridge Market Research también incluye un análisis experto en profundidad, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.
Alcance del informe y segmentación del mercado
|
Métrica del informe |
Detalles |
|
Período de pronóstico |
2022 a 2029 |
|
Año base |
2021 |
|
Años históricos |
2020 (Personalizable para 2014 - 2019) |
|
Unidades cuantitativas |
Ingresos en miles de millones de USD, volúmenes en unidades, precios en USD |
|
Segmentos cubiertos |
Tipos (Episódica, Migraña con Aura, Crónica y Otras), Tratamiento (Tratamiento Agudo/Abortivo, Tratamiento Preventivo/Profiláctico, Terapias y Dispositivos No Farmacológicos), Vía de Administración (Oral, Parenteral, Aerosoles Nasales y Otros), Tipo de Producto (Recetado y de Venta Libre), Tipo (De Marca y Genérico), Usuario Final (Hospitales, Clínicas, Atención Domiciliaria, Otros), Canal de Distribución (Farmacias Hospitalarias, Farmacias Minoristas, Farmacias Online y Otros) |
|
Países cubiertos |
China, Japón, India, Corea del Sur, Singapur, Malasia, Australia, Tailandia, Indonesia, Filipinas, Resto de Asia-Pacífico (APAC) en Asia-Pacífico (APAC) |
|
Actores del mercado cubiertos |
Pfizer Inc. (U.S), Eli Lilly and Company (U.S), Amgen Inc. (U.S), GSK plc. (U.K), Novartis AG (Switzerland), Bayer AG (Germany), Allergan (Ireland), Abbott (U.S), Allodynic Therapeutics, LLC (U.S), AOBiome (U.S), AstraZeneca (U.K), Aurobindo Pharma USA (U.S), Bausch Health Companies Inc. (Canada), Biohaven Pharmaceuticals (U.S), Boehringer Ingelheim International GmbH (Germany), Catalent, Inc (U.S), Dr. Reddy’s Laboratories Ltd. (India), Impel Pharmaceuticals Inc. (U.S), H. Lundbeck A/S (Denmark), Merck & Co., Inc (U.S) |
|
Market Opportunities |
|
Market Definition
Migraine is a life-threatening neurological condition marked by recurring attacks of severe throbbing head pain that can last up to three days. The headaches can last anywhere from four hours to three days and are usually unilateral. Other symptoms that are usually associated with pain include nausea, vomiting, increased sensitivity to light (photophobia), increased sensitivity to sound (phonophobia), tingling or numbness in the extremities or legs, sweating, and diarrhoea.
Migraine Treatment Market Dynamics
Drivers
- Rise in the prevalence and diagnosis of migraine
A huge increase in migraine is a primary factor driving market expansion. Aside from that, the market is benefiting from improved reimbursement policies for migraine treatments and the rising demand for precision medicines. Additionally, rising demand for electrical nerve stimulating devices to treat migraines and the expected approval of new classes of late-stage pipeline drugs with higher clinical efficacy, such as the introduction of calcitonin gene-related peptide (CGRP) monoclonal antibodies, are propelling market growth.
- Significant advances are currently being made in the prophylactic treatment of CM
These significant advancements should prompt us to reconsider our approach to this devastating disease and empower us to remain vigilant and continue scientific clinical research, keeping in mind that only a common, shared clinical and scientific management strategy will improve CM detection, distinguish phenotypes and biological markers, shed light on neglected clinical governance areas, provide individualised healthcare and tailored therapy, and optimise the allocation of economic resources. It is our responsibility to guarantee that novel and evolving therapeutic options, such as OBT-A and anti-CGRP monoclonal antibodies, are fully utilised as part of a broader preventative culture in order to substantially reduce the human, societal, and economic consequences of this fatal disease.
- Increase in focus of vendors on the emerging markets
Asia-Pacific and Latin America and the Caribbean are likely to drive market growth. Due to increased demand for better healthcare facilities and advances in healthcare infrastructure, Asia-Pacific is expected to grow significantly in the future. Furthermore, because the developed markets are somewhat saturated, this region presents exceptional potential for venture capitalists and investors.
Opportunities
Raised research and development (R&D) expenditure in migraine therapy leads to pipeline goods, which will result in manufacturers putting new medicines into the market, raising demand, and technological advancement for the treatment of acute migraine has increased demand. Several research projects are now underway, which will likely give manufacturers a competitive advantage in generating new, innovative, and enhanced migraine treatment drugs as well as other migraine therapy prospects.
Restraints/Challenges
However, use of alternative therapies such as homeopathy and limitations of current migraine therapies, a decline in clinical visits and procedural treatment of migraines due to social distancing norms expected to restraint the market growth in the forecast period 2022 to 2029.
This migraine treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the migraine treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Migraine Treatment Market
The neurologic indications of COVID-19 indicate that the virus entered the nervous system by the olfactory groove or the circulation. Numerous studies have connected COVID-19 mortality to cardiac and pulmonary disorders. Migraine also produces a higher rate of vascular problems, putting migraine sufferers at a higher risk of unsatisfactory COVID-19 results. COVID-19 acute symptoms such as fever, insomnia, and dehydration might set to a migraine episode. COVID-19 headaches were described as pulsing, pressing, or stabbing. They were mostly bilateral, lasted longer, were resistant to analgesia, and were more common in men. Migraine sufferers are especially sensitive to the pandemic's long-term and indirect effects, such as depression, tiredness from the virus, and anxiety.
Recent Development
- En febrero de 2022, Rimegepant, un antagonista del receptor del péptido relacionado con el gen de la calcitonina (CGRP), recibió una opinión favorable del Comité de Medicamentos de Uso Humano (CHMP) de la Agencia Europea de Medicamentos (EMA), según Biohaven Pharmaceutical Holding Company Ltd. y Pfizer Inc. Se recomienda para la autorización de comercialización como dosis de 75 mg de Rimegepant (disponible como comprimido de disolución oral) para el tratamiento agudo de la migraña con o sin aura en adultos, así como para el tratamiento preventivo de la migraña episódica en adultos que tienen al menos cuatro ataques de migraña al mes.
- En enero de 2022, Elyxyb (solución oral de celecoxib) es un nuevo líquido de acción rápida de BioDelivery Sciences. Es uno de los primeros tratamientos orales listos para usar aprobados por la FDA para personas que sufren migraña aguda con o sin aura.
Alcance del mercado de tratamiento de la migraña en Asia y el Pacífico
El mercado de tratamiento de la migraña está segmentado en función del tipo, el tratamiento, la vía de administración, el producto, el canal de distribución y el usuario final. El crecimiento entre estos segmentos le ayudará a analizar los segmentos de crecimiento reducido de las industrias y brindará a los usuarios una valiosa descripción general del mercado y conocimientos del mercado para ayudarlos a tomar decisiones estratégicas para identificar las principales aplicaciones del mercado.
Tipos
- Episódico
- Migraña con aura
- Crónico
- Otros
Tratamiento
- Tratamiento agudo/abortivo
- Tratamiento preventivo/profiláctico
- Terapias y dispositivos no farmacológicos
Vía de administración
- Oral
- Parenteral
Producto
- Prescripción
- En el mostrador
Tipo
- De marca
- Genérico
Usuario final
- Hospitales
- Clínicas
- Cuidado domiciliario
- Otros
Canal de distribución
- Farmacias hospitalarias
- Farmacias minoristas
- Farmacias en línea
- Otros
Análisis y perspectivas regionales del mercado de tratamiento de la migraña
Se analiza el mercado de tratamiento de la migraña y se proporcionan información y tendencias del tamaño del mercado por país, tipo, tratamiento, vía de administración, producto, canal de distribución y usuario final como se mencionó anteriormente.
Los países cubiertos en el informe del mercado de tratamiento de la migraña son China, Japón, India, Corea del Sur, Singapur, Malasia, Australia, Tailandia, Indonesia, Filipinas, Resto de Asia-Pacífico (APAC) en Asia-Pacífico (APAC).
China domina el mercado de tratamiento de la migraña en Asia-Pacífico porque la industria farmacéutica es una de las principales industrias del país, con un número cada vez mayor de inversores. El enfoque en el crecimiento orgánico, la creciente urbanización y los cambios en los ingresos disponibles son variables importantes que influyen en el mercado.
La sección de países del informe también proporciona factores de impacto de mercado individuales y cambios en la regulación en el mercado a nivel nacional que afectan las tendencias actuales y futuras del mercado. Puntos de datos como análisis de la cadena de valor aguas abajo y aguas arriba, tendencias técnicas y análisis de las cinco fuerzas de Porter, estudios de casos son algunos de los indicadores utilizados para pronosticar el escenario del mercado para países individuales. Además, la presencia y disponibilidad de marcas globales y sus desafíos enfrentados debido a la competencia grande o escasa de las marcas locales y nacionales, el impacto de los aranceles nacionales y las rutas comerciales se consideran al proporcionar un análisis de pronóstico de los datos del país.
Crecimiento de la infraestructura de salud Base instalada y penetración de nuevas tecnologías
El mercado de tratamiento de la migraña también le proporciona un análisis detallado del mercado para cada país: crecimiento del gasto sanitario en equipos de capital, base instalada de diferentes tipos de productos para el mercado de tratamiento de la migraña, impacto de la tecnología mediante curvas de línea de vida y cambios en los escenarios regulatorios de la atención médica y su impacto en el mercado de tratamiento de la migraña. Los datos están disponibles para el período histórico 2010-2020.
Análisis del panorama competitivo y de la cuota de mercado del tratamiento de la migraña
El panorama competitivo del mercado de tratamiento de la migraña proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia global, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, la amplitud y la variedad de productos, el dominio de las aplicaciones. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas en relación con el mercado de tratamiento de la migraña.
Algunos de los principales actores que operan en el mercado del tratamiento de la migraña son:
- Pfizer Inc. (Estados Unidos)
- Eli Lilly and Company (Estados Unidos)
- Amgen Inc. (Estados Unidos)
- GSK plc. (Reino Unido)
- Novartis AG (Suiza)
- Bayer AG (Alemania)
- Allergan (Irlanda)
- Abbott (Estados Unidos)
- Allodynic Therapeutics, LLC (Estados Unidos)
- AOBiome (Estados Unidos)
- AstraZeneca (Reino Unido)
- Aurobindo Pharma USA (Estados Unidos)
- Bausch Health Companies Inc. (Canadá)
- Biohaven Pharmaceuticals (Estados Unidos)
- Boehringer Ingelheim International GmbH (Alemania)
- Catalent, Inc. (Estados Unidos)
- Laboratorios Dr. Reddy Ltd. (India)
- Impel Pharmaceuticals Inc. (Estados Unidos)
- H. Lundbeck A/S (Dinamarca)
- Merck & Co., Inc (Estados Unidos)
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA PACIFIC MIGRAINE TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPES OF MIGRAINE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.1.1 INCREASING PREVALENCE OF MIGRAINE
3.1.2 GROWING FEMALE POPULATION
3.1.3 DEVELOPMENT OF NOVEL DRUGS
3.1.4 RISING AWARENESS PROGRAMS
3.1.5 AVAILABILITY OF LARGE NUMBER OF GENERIC DRUGS
3.2 RESTRAINTS
3.2.1 RECALL OF DRUGS
3.2.2 ADVERSE EFFECTS OF DRUGS
3.3 OPPORTUNITIES
3.3.1 TECHNOLOGICAL ADVANCEMENTS FOR THE TREATMENT OF ACUTE MIGRAINE
3.3.2 INCREASING R&D INVESTMENT LEADING TO PIPELINE PRODUCTS
3.3.3 RISING COLLABORATIONS, AND MERGER & ACQUISITIONS AMONG THE MARKET PLAYERS
3.4 CHALLENGES
3.4.1 USE OF ALTERNATIVE THERAPIES SUCH AS HOMEOPATHY
3.4.2 LIMITATIONS OF CURRENT MIGRAINE THERAPIES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
6 EPIDEMIOLOGY
7 REIMBURSEMENT SCENARIO & REGULATION STATUS
7.1 REIMBURSEMENT SCENARIO
7.2 REGULATIONS
8 PIPELINE ANALYSIS
9 IMPACT OF COVID 19 PANDEMIC ON THE MARKET
9.1 PRICE IMPACT
9.2 IMPACT ON DEMAND
9.3 IMPACT ON SUPPLY CHAIN
9.4 STRATEGIC DECISIONS FOR MANUFACTURERS
9.5 CONCLUSION
10 ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE
10.1 OVERVIEW
10.2 EPISODIC
10.3 MIGRAINE WITH AURA
10.4 CHRONIC
10.5 OTHERS
11 ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY TREATMENT
11.1 OVERVIEW
11.2 ACUTE/ABORTIVE TREATMENT
11.2.1 NONSPECIFIC THERAPIES
11.2.1.1 TRIPTANS
11.2.1.1.1 SUMATRIPTAN
11.2.1.1.2 RIZATRIPTAN
11.2.1.1.3 OTHERS
11.2.1.2 OPIATES/OPOIDS
11.2.1.2.1 VICODIN
11.2.1.2.2 OXYCONTIN
11.2.1.2.3 PERCOCET
11.2.1.2.4 OTHERS
11.2.1.3 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
11.2.1.3.1 ASPIRIN
11.2.1.3.2 IBUPROFEN
11.2.1.3.3 ACETAMINOPHEN
11.2.1.3.4 OTHERS
11.2.1.4 ERGOT ALKALOID
11.2.1.4.1 ERGOTAMINE
11.2.1.4.2 LASMIDITAN
11.2.1.4.3 DIHYDROERGOTAMINES
11.2.1.4.4 OTHERS
11.2.1.5 ANTI-NAUSEA
11.2.1.5.1 PROCHLORPERAZINE
11.2.1.5.2 METOCLOPRAMIDE
11.2.1.5.3 CHLORPROMAZINE
11.2.1.5.4 OTHERS
11.2.1.6 OTHERS
11.2.2 ADJUNCTIVE THERAPIES
11.2.2.1 ANTIEMETICS
11.2.2.2 SEDATIVES
11.2.2.3 OTHERS
11.2.3 OTHERS
11.2.3.1 INTRANASAL LIDOCAINE
11.2.3.2 STEROIDS
11.2.3.3 OTHERS
11.3 PREVENTIVE/PROPHYLACTIC TREATMENT
11.3.1 ANTICONVULSANTS
11.3.1.1 TOPAMAX (TOPIRAMATE)
11.3.1.2 TROKENDI (TOPIRAMATE)
11.3.1.3 DEPAKOTE (DIVALPROEX SODIUM)
11.3.1.4 QUDEXY XR (TOPIRAMATE)
11.3.1.5 OTHERS
11.3.2 CALCITONIN GENE-RELATED PEPTIDE THERAPY
11.3.2.1 ERENUMAB-AOOE
11.3.2.2 GALCANEZUMAB
11.3.2.3 FREMANEZUMAB-VFRM
11.3.2.4 OTHERS
11.3.3 SELECTIVE SEROTONIN RECEPTOR AGONISTS
11.3.3.1 SUMATRIPTAN
11.3.3.2 RIZATRIPTAN
11.3.3.3 ZOLMITRIPTAN
11.3.3.4 ELETRIPTAN
11.3.3.5 FROVATRIPTAN
11.3.3.6 NARATRIPTAN
11.3.3.7 ALMOTRIPTAN MALATE
11.3.3.8 OTHERS
11.3.4 ANTIDEPRESSANTS
11.3.4.1 AMITRIPTYLINE
11.3.4.2 NORTRIPTYLINE
11.3.4.3 OTHERS
11.3.5 NSAIDS
11.3.5.1 NAPROXEN SODIUM
11.3.5.2 NAPROXEN
11.3.5.3 KETOPROFEN
11.3.5.4 FENOPROFEN
11.3.5.5 OTHERS
11.3.6 BLOOD PRESSURE-LOWERING MEDICATIONS
11.3.6.1 BETA BLOCKERS
11.3.6.1.1 PROPRANAOLOL
11.3.6.1.2 TIMOLOL
11.3.6.1.3 OTHERS
11.3.6.2 CALCIUM-CHANNEL BLOCKERS
11.3.6.2.1 VERAPAMIL
11.3.6.2.2 NIMODIPINE
11.3.6.2.3 OTHERS
11.3.7 ANGIOTENSIN BLOCKERS: ACE-IS/ARBS
11.3.7.1 CANDESARTAN
11.3.7.2 TELMISARTAN
11.3.7.3 OTHERS
11.3.8 OTHERS
11.4 NON-PHARMACOLOGICAL THERAPIES
11.4.1 ACUPUNCTURE
11.4.2 BIOFEEDBACK TECHNIQUES
11.4.3 COGNITIVE BEHAVIOR THERAPY
11.4.4 MASSAGE
11.4.5 RELAXATION
11.4.6 OTHERS
11.5 DEVICES
11.5.1 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS)
11.5.2 OTHERS
12 ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 ORAL
12.3 PARENTERAL
12.4 NASAL SPRAYS
12.5 OTHERS
13 ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE
13.1 OVERVIEW
13.2 PRESCRIPTION
13.3 OVER THE COUNTER
14 ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY TYPE
14.1 OVERVIEW
14.2 GENERIC
14.3 BRANDED
15 ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 CLINICS
15.4 HOMECARE
15.5 OTHERS
16 ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 HOSPITAL PHARMACIES
16.3 RETAIL PHARMACIES
16.4 ONLINE PHARMACIES
16.5 OTHERS
17 ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY GEOGRAPHY
17.1 ASIA-PACIFIC
17.1.1 CHINA
17.1.2 JAPAN
17.1.3 INDIA
17.1.4 SOUTH KOREA
17.1.5 AUSTRALIA
17.1.6 SINGAPORE
17.1.7 INDONESIA
17.1.8 THAILAND
17.1.9 MALAYSIA
17.1.10 PHILIPPINES
17.1.11 VIETNAM
17.1.12 REST OF ASIA-PACIFIC
18 ASIA PACIFIC MIGRAINE TREATMENT MARKET, COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
19 SWOT ANALYSIS AND DATA BRIDGE MARKET RESEARCH ANALYSIS
19.1 SWOT ANALYSIS
19.1.1 STRENGTH
19.1.1.1 STRONG PRODUCT PORTFOLIO
19.1.1.2 ASIA PACIFIC COMMERCIAL PRESENCE IN EMERGING MARKETS
19.1.2 WEAKNESS
19.1.2.1 DEPENDENCY ON THIRD PARTIES FOR RESEARCH AND DEVELOPMENT
19.1.2.2 LITIGATION AND GOVERNMENT INVESTIGATION
19.1.3 OPPORTUNITY
19.1.3.1 EXPANDING BUSINESS THOROUGH THEIR SUBSIDIARIES
19.1.3.2 STRATEGIC INITIATIVES
19.1.4 THREAT
19.1.4.1 COMPETITIVE ENVIRONMENT
19.2 ASIA PACIFIC MIGRAINE TREATMENT MARKET: DBMR ANALYSIS
20 COMPANY PROFILE
20.1 AMGEN INC.
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 COMPANY SHARE ANALYSIS
20.1.4 PRODUCT PORTFOLIO
20.1.5 RECENT DEVELOPMENTS
20.2 ELI LILLY AND COMPANY
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE ANALYSIS
20.2.3 COMPANY SHARE ANALYSIS
20.2.4 PRODUCT PORTFOLIO
20.2.5 RECENT DEVELOPMENTS
20.3 GLAXOSMITHKLINE PLC.
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 COMPANY SHARE ANALYSIS
20.3.4 PRODUCT PORTFOLIO
20.3.5 RECENT DEVELOPMENTS
20.4 NOVARTIS AG
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE ANALYSIS
20.4.3 COMPANY SHARE ANALYSIS
20.4.4 PRODUCT PORTFOLIO
20.4.5 RECENT DEVELOPMENTS
20.5 BAYER AG
20.5.1 COMPANY SNAPSHOT
20.5.2 REVENUE ANALYSIS
20.5.3 COMPANY SHARE ANALYSIS
20.5.4 PRODUCT PORTFOLIO
20.5.5 RECENT DEVELOPMENT
20.6 ALLERGAN
20.6.1 COMPANY SNAPSHOT
20.6.2 REVENUE ANALYSIS
20.6.3 PRODUCT PORTFOLIO
20.6.4 RECENT DEVELOPMENTS
20.7 ABBOTT
20.7.1 COMPANY SNAPSHOT
20.7.2 REVENUE ANALYSIS
20.7.3 PRODUCT PORTFOLIO
20.7.4 RECENT DEVELOPMENTS
20.8 ALLODYNIC THERAPEUTICS, LLC
20.8.1 COMPANY SNAPSHOT
20.8.2 PRODUCT PORTFOLIO
20.8.3 RECENT DEVELOPMENT
20.9 AOBIOME
20.9.1 COMPANY SNAPSHOT
20.9.2 PRODUCT PORTFOLIO
20.9.3 RECENT DEVELOPMENTS
20.1 ASTRAZENECA
20.10.1 COMPANY SNAPSHOT
20.10.2 REVENUE ANALYSIS
20.10.3 PRODUCT PORTFOLIO
20.10.4 RECENT DEVELOPMENTS
20.11 AUROBINDO PHARMA USA (A SUBSIDIARY OF AUROBINDO PHARMA)
20.11.1 COMPANY SNAPSHOT
20.11.2 REVENUE ANALYSIS
20.11.3 PRODUCT PORTFOLIO
20.11.4 RECENT DEVELOPMENTS
20.12 BAUSCH HEALTH COMPANIES INC.
20.12.1 COMPANY SNAPSHOT
20.12.2 REVENUE ANALYSIS
20.12.3 PRODUCT PORTFOLIO
20.12.4 RECENT DEVELOPMENT
20.13 BIOHAVEN PHARMACEUTICALS
20.13.1 COMPANY SNAPSHOT
20.13.2 REVENUE ANALYSIS
20.13.3 PRODUCT PORTFOLIO
20.13.4 RECENT DEVELOPMENTS
20.14 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
20.14.1 COMPANY SNAPSHOT
20.14.2 REVENUE ANALYSIS
20.14.3 PRODUCT PORTFOLIO
20.14.4 RECENT DEVELOPMENTS
20.15 CATALENT, INC
20.15.1 COMPANY SNAPSHOT
20.15.2 REVENUE ANALYSIS
20.15.3 PRODUCT PORTFOLIO
20.15.4 RECENT DEVELOPMENTS
20.16 DR. REDDY’S LABORATORIES LTD.
20.16.1 COMPANY SNAPSHOT
20.16.2 REVENUE ANALYSIS
20.16.3 PRODUCT PORTFOLIO
20.16.4 RECENT DEVELOPMENTS
20.17 IMPEL NEUROPHARMA, INC.
20.17.1 COMPANY SNAPSHOT
20.17.2 PRODUCT PORTFOLIO
20.17.3 RECENT DEVELOPMENTS
20.18 LUNDBECK
20.18.1 COMPANY SNAPSHOT
20.18.2 REVENUE ANALYSIS
20.18.3 PRODUCT PORTFOLIO
20.18.4 RECENT DEVELOPMENTS
20.19 MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.)
20.19.1 COMPANY SNAPSHOT
20.19.2 REVENUE ANALYSIS
20.19.3 PRODUCT PORTFOLIO
20.19.4 RECENT DEVELOPMENTS
20.2 NEURELIS, INC.
20.20.1 COMPANY SNAPSHOT
20.20.2 PRODUCT PORTFOLIO
20.20.3 RECENT DEVELOPMENTS
20.21 OTSUKA PHARMACEUTICAL CO., LTD. (A SUBSIDIARY OF OTSUKA HOLDINGS CO., LTD.)
20.21.1 COMPANY SNAPSHOT
20.21.2 REVENUE ANALYSIS
20.21.3 PRODUCT PORTFOLIO
20.21.4 RECENT DEVELOPMENTS
20.22 PFIZER INC.
20.22.1 COMPANY SNAPSHOT
20.22.2 REVENUE ANALYSIS
20.22.3 PRODUCT PORTFOLIO
20.22.4 RECENT DEVELOPMENTS
20.23 SUN PHARMACEUTICAL INDUSTRIES LTD.
20.23.1 COMPANY SNAPSHOT
20.23.2 REVENUE ANALYSIS
20.23.3 PRODUCT PORTFOLIO
20.23.4 RECENT DEVELOPMENTS
20.24 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICALS INDUSTRIES LTD.)
20.24.1 COMPANY SNAPSHOT
20.24.2 REVENUE ANALYSIS
20.24.3 PRODUCT PORTFOLIO
20.24.4 RECENT DEVELOPMENTS
20.25 ZOSANO PHARMA CORPORATION
20.25.1 COMPANY SNAPSHOT
20.25.2 REVENUE ANALYSIS
20.25.3 PRODUCT PORTFOLIO
20.25.4 RECENT DEVELOPMENTS
21 CONCLUSION
22 QUESTIONNAIRE
23 RELATED REPORTS
Lista de Tablas
LIST OF TABLES
TABLE 1 GENERIC DRUGS FOR MIGRAINE TREATMENT
TABLE 2 PIPELINE DRUGS FOR MIGRAINE TREATMENT
TABLE 3 ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY PIPELINE ANALYSIS
TABLE 4 ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 5 ASIA PACIFIC EPISODIC IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 6 ASIA PACIFIC MIGRAINE WITH AURA IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 7 ASIA PACIFIC CHRONIC IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 8 ASIA PACIFIC OTHERS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 9 ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 10 ASIA PACIFIC ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 11 ASIA PACIFIC ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 12 ASIA PACIFIC NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TRAETMENT, 2018-2027 (USD MILLION)
TABLE 13 ASIA PACIFIC TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 14 ASIA PACIFIC OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 15 ASIA PACIFIC NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 16 ASIA PACIFIC ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 17 ASIA PACIFIC ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 18 ASIA PACIFIC ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 19 ASIA PACIFIC OTHERS IN MIGRAINE TREATMENT MARKET, BY TRATMENT, 2018-2027 (USD MILLION)
TABLE 20 ASIA PACIFIC PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 21 ASIA PACIFIC PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 22 ASIA PACIFIC ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 23 ASIA PACIFIC CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 24 ASIA PACIFIC SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 25 ASIA PACIFIC ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 26 ASIA PACIFIC NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 27 ASIA PACIFIC BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 28 ASIA PACIFIC BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 29 ASIA PACIFIC CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 30 ASIA PACIFIC ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 31 ASIA PACIFIC NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 32 ASIA PACIFIC NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 33 ASIA PACIFIC DEVICES IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 34 ASIA PACIFIC DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 35 ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 36 ASIA PACIFIC ORAL IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 37 ASIA PACIFIC PARENTERAL IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 38 ASIA PACIFIC NASAL SPRAYS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 39 ASIA PACIFIC OTHERS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 40 ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 41 ASIA PACIFIC PRESCRIPTION IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 42 ASIA PACIFIC OVER THE COUNTER IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 43 ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 44 ASIA PACIFIC GENERIC IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 45 ASIA PACIFIC BRANDED IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 46 ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 47 ASIA PACIFIC HOSPITALS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 48 ASIA PACIFIC CLINICS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 49 ASIA PACIFIC HOMECARE IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 50 ASIA PACIFIC OTHERS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 51 ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 52 ASIA PACIFIC HOSPITAL PHARMACIES IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 53 ASIA PACIFIC RETAIL PHARMACIES IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 54 ASIA PACIFIC ONLINE PHARMACIES IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 55 ASIA PACIFIC OTHERS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 56 ASIA-PACIFIC MIGRAINE TREATMENT MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 57 ASIA-PACIFIC MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 58 ASIA-PACIFIC MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 59 ASIA-PACIFIC ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 60 ASIA-PACIFIC NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 61 ASIA-PACIFIC TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 62 ASIA-PACIFIC OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 63 ASIA-PACIFIC NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 64 ASIA-PACIFIC ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 65 ASIA-PACIFIC ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 66 ASIA-PACIFIC ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 67 ASIA-PACIFIC OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 68 ASIA-PACIFIC PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 69 ASIA-PACIFIC ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 70 ASIA-PACIFIC CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 71 ASIA-PACIFIC SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 72 ASIA-PACIFIC ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 73 ASIA-PACIFIC NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 74 ASIA-PACIFIC BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 75 ASIA-PACIFIC BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 76 ASIA-PACIFIC CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 77 ASIA-PACIFIC ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 78 ASIA-PACIFIC NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 79 ASIA-PACIFIC DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 80 ASIA-PACIFIC MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 81 ASIA-PACIFIC MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 82 ASIA-PACIFIC MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 83 ASIA-PACIFIC MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 84 ASIA-PACIFIC MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 85 CHINA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 86 CHINA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 87 CHINA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 88 CHINA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 89 CHINA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 90 CHINA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 91 CHINA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 92 CHINA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 93 CHINA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 94 CHINA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 95 CHINA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 96 CHINA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 97 CHINA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 98 CHINA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD)
TABLE 99 CHINA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 100 CHINA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 101 CHINA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 102 CHINA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 103 CHINA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 104 CHINA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 105 CHINA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 106 CHINA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 107 CHINA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 108 CHINA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 109 CHINA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 110 CHINA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 111 CHINA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 112 CHINA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 113 JAPAN MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 114 JAPAN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 115 JAPAN ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 116 JAPAN NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 117 JAPAN TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 118 JAPAN OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 119 JAPAN NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 120 JAPAN ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 121 JAPAN ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 122 JAPAN ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 123 JAPAN OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 124 JAPAN PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 125 JAPAN ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 126 JAPAN CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 127 JAPAN SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 128 JAPAN ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 129 JAPAN NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 130 JAPAN BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 131 JAPAN BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 132 JAPAN CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 133 JAPAN ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 134 JAPAN NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 135 JAPAN DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 136 JAPAN MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 137 JAPAN MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 138 JAPAN MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 139 JAPAN MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 140 JAPAN MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 141 INDIA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 142 INDIA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 143 INDIA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 144 INDIA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 145 INDIA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 146 INDIA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 147 INDIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 148 INDIA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 149 INDIA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 150 INDIA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 151 INDIA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 152 INDIA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 153 INDIA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 154 INDIA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 155 INDIA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 156 INDIA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 157 INDIA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 158 INDIA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 159 INDIA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 160 INDIA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 161 INDIA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 162 INDIA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 163 INDIA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 164 INDIA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 165 INDIA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 166 INDIA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 167 INDIA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 168 INDIA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 169 SOUTH KOREA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 170 SOUTH KOREA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 171 SOUTH KOREA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 172 SOUTH KOREA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 173 SOUTH KOREA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 174 SOUTH KOREA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 175 SOUTH KOREA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 176 SOUTH KOREA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 177 SOUTH KOREA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 178 SOUTH KOREA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 179 SOUTH KOREA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 180 SOUTH KOREA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 181 SOUTH KOREA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 182 SOUTH KOREA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 183 SOUTH KOREA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 184 SOUTH KOREA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 185 SOUTH KOREA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 186 SOUTH KOREA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 187 SOUTH KOREA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 188 SOUTH KOREA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 189 SOUTH KOREA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 190 SOUTH KOREA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 191 SOUTH KOREA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 192 SOUTH KOREA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 193 SOUTH KOREA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 194 SOUTH KOREA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 195 SOUTH KOREA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 196 SOUTH KOREA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 197 AUSTRALIA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 198 AUSTRALIA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 199 AUSTRALIA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 200 AUSTRALIA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 201 AUSTRALIA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 202 AUSTRALIA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 203 AUSTRALIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 204 AUSTRALIA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 205 AUSTRALIA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 206 AUSTRALIA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 207 AUSTRALIA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 208 AUSTRALIA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 209 AUSTRALIA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 210 AUSTRALIA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 211 AUSTRALIA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 212 AUSTRALIA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 213 AUSTRALIA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 214 AUSTRALIA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 215 AUSTRALIA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 216 AUSTRALIA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 217 AUSTRALIA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 218 AUSTRALIA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 219 AUSTRALIA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 220 AUSTRALIA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 221 AUSTRALIA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 222 AUSTRALIA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 223 AUSTRALIA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 224 AUSTRALIA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 225 SINGAPORE MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 226 SINGAPORE MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 227 SINGAPORE ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 228 SINGAPORE NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 229 SINGAPORE TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 230 SINGAPORE OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 231 SINGAPORE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 232 SINGAPORE ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 233 SINGAPORE ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 234 SINGAPORE ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 235 SINGAPORE OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 236 SINGAPORE PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 237 SINGAPORE ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 238 SINGAPORE CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 239 SINGAPORE SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 240 SINGAPORE ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 241 SINGAPORE NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 242 SINGAPORE BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 243 SINGAPORE BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 244 SINGAPORE CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 245 SINGAPORE ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 246 SINGAPORE NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 247 SINGAPORE DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 248 SINGAPORE MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 249 SINGAPORE MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 250 SINGAPORE MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 251 SINGAPORE MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 252 SINGAPORE MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 253 INDONESIA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 254 INDONESIA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 255 INDONESIA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 256 INDONESIA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 257 INDONESIA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 258 INDONESIA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 259 INDONESIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 260 INDONESIA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 261 INDONESIA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 262 INDONESIA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 263 INDONESIA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 264 INDONESIA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 265 INDONESIA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 266 INDONESIA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 267 INDONESIA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 268 INDONESIA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 269 INDONESIA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 270 INDONESIA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 271 INDONESIA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 272 INDONESIA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 273 INDONESIA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 274 INDONESIA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 275 INDONESIA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 276 INDONESIA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 277 INDONESIA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 278 INDONESIA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 279 INDONESIA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 280 INDONESIA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 281 THAILAND MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 282 THAILAND MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 283 THAILAND ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 284 THAILAND NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 285 THAILAND TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 286 THAILAND OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 287 THAILAND NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 288 THAILAND ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 289 THAILAND ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 290 THAILAND ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 291 THAILAND OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 292 THAILAND PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 293 THAILAND ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 294 THAILAND CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 295 THAILAND SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 296 THAILAND ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 297 THAILAND NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 298 THAILAND BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 299 THAILAND BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 300 THAILAND CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 301 THAILAND ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 302 THAILAND NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 303 THAILAND DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 304 THAILAND MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 305 THAILAND MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 306 THAILAND MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 307 THAILAND MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 308 THAILAND MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 309 MALAYSIA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 310 MALAYSIA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 311 MALAYSIA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 312 MALAYSIA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 313 MALAYSIA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 314 MALAYSIA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 315 MALAYSIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 316 MALAYSIA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 317 MALAYSIA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 318 MALAYSIA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 319 MALAYSIA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 320 MALAYSIA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 321 MALAYSIA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 322 MALAYSIA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 323 MALAYSIA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 324 MALAYSIA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 325 MALAYSIA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 326 MALAYSIA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 327 MALAYSIA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 328 MALAYSIA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 329 MALAYSIA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 330 MALAYSIA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 331 MALAYSIA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 332 MALAYSIA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 333 MALAYSIA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 334 MALAYSIA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 335 MALAYSIA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 336 MALAYSIA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 337 PHILIPPINES MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 338 PHILIPPINES MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 339 PHILIPPINES ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 340 PHILIPPINES NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 341 PHILIPPINES TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 342 PHILIPPINES OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 343 PHILIPPINES NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 344 PHILIPPINES ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 345 PHILIPPINES ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 346 PHILIPPINES ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 347 PHILIPPINES OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 348 PHILIPPINES PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 349 PHILIPPINES ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 350 PHILIPPINES CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 351 PHILIPPINES SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 352 PHILIPPINES ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 353 PHILIPPINES NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 354 PHILIPPINES BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 355 PHILIPPINES BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 356 PHILIPPINES CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 357 PHILIPPINES ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 358 PHILIPPINES NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 359 PHILIPPINES DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 360 PHILIPPINES MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 361 PHILIPPINES MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 362 PHILIPPINES MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 363 PHILIPPINES MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 364 PHILIPPINES MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 365 VIETNAM MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 366 VIETNAM MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 367 VIETNAM ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 368 VIETNAM NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 369 VIETNAM TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 370 VIETNAM OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 371 VIETNAM NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 372 VIETNAM ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 373 VIETNAM ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 374 VIETNAM ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 375 VIETNAM OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 376 VIETNAM PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 377 VIETNAM ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 378 VIETNAM CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 379 VIETNAM SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 380 VIETNAM ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 381 VIETNAM NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 382 VIETNAM BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 383 VIETNAM BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 384 VIETNAM CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 385 VIETNAM ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 386 VIETNAM NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 387 VIETNAM DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 388 VIETNAM MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 389 VIETNAM MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 390 VIETNAM MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 391 VIETNAM MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 392 VIETNAM MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 393 REST OF ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 394 SUBSIDIARIES OF JANSSEN ASIA PACIFIC SERVICES, LLC
Lista de figuras
LIST OF FIGURES
FIGURE 1 ASIA PACIFIC MIGRAINE TREATMENT MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC MIGRAINETREATMENT MARKET : DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC MIGRAINE TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC MIGRAINE TREATMENT MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC MIGRAINE TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC MIGRAINE TREATMENT MARKET: MULTIVARIATE MODELLING
FIGURE 7 ASIA PACIFIC MIGRIANE TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 ASIA PACIFIC MIGRIANE TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA PACIFIC MIGRIANE TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF ASIA PACIFIC MIGRAINE TREATMENT MARKET
FIGURE 11 RESULT OF PREVALENCE OF MIGRAINE FROM ONE YEAR STUDY
FIGURE 12 ASIA PACIFIC MIGRAINE TREATMENT MARKET: SEGMENTATION
FIGURE 13 INCREASING PREVALNCE OF MIGRAINE AND DEVELOPMENT OF NOVEL DRUGS IS DRIVING THE ASIA PACIFIC MIGRIANE TREATMENT MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 14 EPISODIC IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC MIGRAINE TREATMENT MARKET IN 2020 & 2027
FIGURE 15 ASIA-PACIFIC IS THE FASTEST GROWING MARKET IN ASIA PACIFIC MIGRAINE TREATMENT MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 16 ASIA PACIFIC PREVALENCE OF MIGRAINE TREATMENT (2018)
FIGURE 17 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY TYPES OF MIGRAINE, 2019
FIGURE 18 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY TYPES OF MIGRAINE, 2019-2027 (USD MILLION)
FIGURE 19 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY TYPES OF MIGRAINE, CAGR (2020-2027)
FIGURE 20 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY TYPES OF MIGRAINE, LIFELINE CURVE
FIGURE 21 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY TREATMENT, 2019
FIGURE 22 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY TREATMENT, 2019-2027 (USD MILLION)
FIGURE 23 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY TREATMENT, CAGR (2020-2027)
FIGURE 24 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 25 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2019
FIGURE 26 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
FIGURE 27 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2027)
FIGURE 28 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 29 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY PRODUCT TYPE, 2019
FIGURE 30 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY PRODUCT TYPE, 2019-2027 (USD MILLION)
FIGURE 31 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY PRODUCT TYPE, CAGR (2020-2027)
FIGURE 32 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 33 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY TYPE, 2019
FIGURE 34 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY TYPE, 2019-2027 (USD MILLION)
FIGURE 35 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY TYPE, CAGR (2020-2027)
FIGURE 36 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 37 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY END USER, 2019
FIGURE 38 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY END USER, 2019-2027 (USD MILLION)
FIGURE 39 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY END USER, CAGR (2020-2027)
FIGURE 40 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 41 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2019
FIGURE 42 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
FIGURE 43 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027)
FIGURE 44 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 45 ASIA-PACIFIC MIGRAINE TREATMENT MARKET: SNAPSHOT (2019)
FIGURE 46 ASIA-PACIFIC MIGRAINE TREATMENT MARKET: BY COUNTRY (2019)
FIGURE 47 ASIA-PACIFIC MIGRAINE TREATMENT MARKET: BY COUNTRY (2020 & 2027)
FIGURE 48 ASIA-PACIFIC MIGRAINE TREATMENT MARKET: BY COUNTRY (2019 & 2027)
FIGURE 49 ASIA-PACIFIC MIGRAINE TREATMENT MARKET: BY TYPES OF MIGRAINE (2020-2027)
FIGURE 50 ASIA-PACIFIC MIGRAINE TREATMENT MARKET: COMPANY SHARE 2019 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
